Reata Pharmaceuticals Inc. (RETA)
Symbol Info
Listed Symbol RETA
Name Reata Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $52,351,000
Latest Fiscal EPS $-2.88
Price Info
21 Day Moving Average $85.6733
21 Day EMA $83.957330
50 Day Moving Average $82.0332
50 Day EMA $83.925620
200 Day EMA $80.508220
200 Day Moving Average 83.911900
52 Week High $104.53
52 Week Low $47.50
52 Week Change $61.786600
Alpha 0.048610
Beta 2.3496
Standard Deviation 0.234572
R2 0.111223
Periods 41
Share Information
10 Day Average Volume 358,482
20 Day Average Volume 341,739
30 Day Average Volume 314,446
50 Day Average Volume 279,372
Outstanding Shares 30,106,344
Float Shares 29,810,872
Percent Float 99.02%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 317
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 1,587,609
Institute Holdings Percent 77.800000
Institute Sold Previous 3 Months 1,448,931
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 18
Insider Holdings Percent 1.00%
Insider Sold Previous 3 Months -
Insiders Shares Owned 295,472
Price Change
7 Day Price Change $15.5700000
7 Day Percent Change 19.40%
21 Day Price Change $1.4199982
21 Day Percent Change 1.50%
30 Day Price Change $6.8600006
30 Day Percent Change 7.71%
Month To Date Price Change $15.5200
Month To Date Percent 19.33%
90 Day Price Change $6.610001
90 Day Percent Change 7.41%
Quarter To Date $15.519997
Quarter To Date Percent 19.33%
180 Day Price Change $8.610001
180 Day Percent Change 9.87%
200 Day Price Change $8.750000
200 Day Percent Change 10.05%
Year To Date $39.710000
Year To Date Percent 70.78%
Profile
Description Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening disease by targeting molecular pathways.
Details
Issue Type CS
Market Cap $2,884,488,819
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 30,106,344
CEO J. Warren Huff
Employees 123
Last Audit UE
Classification
CIK 0001358762
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 2801 Gateway Drive
Suite 150
Irving, TX 75063
Website https://www.reatapharma.com
Facisimile
Telephone +1 972 865-2219
Email ir@reatapharma.com
Key Ratios
Profitability
EBIT Margin -377.5
EBITDA Margin -375.3
Pre-Tax Profit Margin -51.3
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $23,438,000
Revenue Per Share $0.9574
Revenue 3 Years $-11.03
Revenue 5 Years $-13.29
Valuation Measures
PE Ratio -
Enterprise Value $2,216,686,359
Price To Sales 100.076294
Price To Free Cash -22.2
PE High Last 5 Years -
Price To Book 63.2
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book -67.1
Financial Strength
Total Debt To Equity -
Int Coverage -11.5
Current Ratio 4.2
Leverage Ratio -9.8
Quick Ratio 4.1
Long Term Debt To Capital -
Assets
Receivables Turnover 0.8
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -50.48
Return On Equity 119.15
Return On Capital -53.6
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
RETA
Reata Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.